WhiteLab Genomics collaborates with the Medicinal Chemistry Laboratory at the Pharmacology institute of Sherbrooke (IPS) to develop peptides targeting new pharmacological targets and optimize viral vectors for genomic medicine
Sherbrooke, Canada – WhiteLab Genomics, a French artificial intelligence tech bio company pioneering advancements in genomic medicine, has announced a collaboration with the Medicinal Chemistry Laboratory led by Professor Pierre-Luc Boudreault at the Institut de Pharmacologie de Sherbrooke (IPS).
About
This partnership will focus on developing peptides that target new pharmacological pathways and optimizing viral vectors to advance precision medicine.
For several months, the teams have been combining their expertise in artificial intelligence, molecular modeling, and medicinal chemistry to enhance the targeting and treatment of cells involved in complex pathologies, particularly those affecting the central nervous system and other degenerative diseases.
Central to this partnership is the validation of novel peptides conceptualized by WhiteLab Genomics through its advanced AI algorithms and molecular modeling tools. These peptides, designed as delivery vehicles, anchor therapeutic molecules precisely to their targets, thereby improving their effectiveness.
In a short time, the collaboration has already yielded promising results, which will be shared in the coming months. Professor Boudreault, along with colleagues Professors Michel Grandbois and Philippe Sarret, is currently testing these AI-generated peptides in the lab to assess their potential. The data collected will be fed back into WhiteLab Genomics’ AI platform, further refining the accuracy of its predictions.
The collaboration
This collaboration offers a tremendous opportunity to showcase the potential of our AI platform, which leverages rich databases alongside the expertise of Professor Boudreault’s team. Our recent expansion into Canada, including the opening of our Montreal office last year, and ongoing collaborations with several Quebec-based laboratories, align with our global vision to accelerate and optimize genomic drug discovery.
By combining our expertise in medicinal chemistry with WhiteLab Genomics' cutting-edge AI platform, we are pushing the boundaries of drug development. This partnership is a prime example of the power of interdisciplinary collaboration in advancing healthcare.
Revolutionizing Drug Discovery through AI and Technological Innovation
Central to this partnership is the validation of novel peptides conceptualized by WhiteLab Genomics through its advanced AI algorithms and molecular modeling tools. These peptides, designed as delivery vehicles, anchor therapeutic molecules precisely to their targets, thereby improving their effectiveness.
In a short time, the collaboration has already produced promising results, which will be shared in the coming months. Professor Boudreault, alongside colleagues Professors Michel Grandbois and Philippe Sarret, is currently testing these AI-generated peptides to assess their potential. The data collected is then fed back into WhiteLab Genomics' AI platform, further refining the accuracy of its predictions.
Media Contact
Follow us on LinkedIn
Nicolas Daniels – Ulysse Communication - ndaniels@ulysse-communication.com
+33 (0)6.63.66.59.22
Martin Sandgren – Klover Communication - press@klovercommunications.com
(949) 438-0425
Photo credits - Matthieu Lanthier, Université de Sherbrooke
